Johnnie Walker The Journey, since its inception, has always told stories of progress. Through Storyline, Johnnie Walker The Journey aims to inspire people by highlighting incredible, real stories that have made a positive difference in the world. Bringing to life its mantra of #KeepWalking, Johnnie Walker The Journey introduces ‘Ode to Lesvos’, the first among a series of short films that aim to inspire people to embrace positivity and bring them together to build a better tomorrow for the world.
Can you really ignore what’s in front of your eyes? Because tomorrow it could be me. I could be on a boat with my family and I would like to be helped,” says fisherman Stratis Valamios in Ode to Lesvos.
This time, 12 months ago, Stratis’ life changed beyond recognition as he spent months on end rescuing men, women and children from the waters around his home. His village, with a population of around 150, became the front line of the refugee crisis as hundreds of thousands of people came ashore, fleeing war and seeking a better future.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7932651-ode-to-lesvos-refugee-crisis/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Nearly three in four American voters (74 percent) favor increasing federal funding for cancer research, according to the results of a new national survey conducted on behalf of the American Association for Cancer Research (AACR). The survey results were released today in conjunction with the AACR’s fifth annual Cancer Progress Report. The report highlights how federally funded research can power progress against cancer and urges Congress and the administration to implement a strategy for providing annual budget increases of at least 7 percent for the National Institutes of Health (NIH), National Cancer Institute (NCI), and U.S. Food and Drug Administration (FDA) in fiscal year 2016 and thereafter.
The national survey, which was conducted by Hart Research Associates and Public Opinion Strategies, shows that five out of every six voters recognize what the AACR Cancer Progress Report 2015 details: that progress is being made against cancer.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613551-aacr-cancer-research-survey/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Georgia Power today marked another year of safe construction and significant milestones at the Vogtle nuclear expansion site. The new units are currently scheduled to go into service in June 2019 (Unit 3) and June 2020 (Unit 4) and the remaining projected customer rate impact is approximately 2.5 percent, an average of less than 1 percent per year through completion.
In addition, the company’s recent completion of the settlement process between the project co-owners (Georgia Power, Oglethorpe Power Corporation, the Municipal Electric Authority of Georgia and Dalton Utilities) and the project’s contractors (Westinghouse and CB&I) settles all claims previously in litigation with the contractors, reaffirms the current in-service dates, adds additional contractual protections and positions Westinghouse and its affiliates as the primary contractor over the project.
To view the multimedia release go to:
http://www.multivu.com/players/English/7464951-ga-power-project-vogtle/
Power and construction partners Westinghouse and CB&I joined community leaders and project workers at a special event to mark a year of progress at the historic expansion of Plant Vogtle near Waynesboro, Ga. Against the backdrop of the nearly complete 600 foot-tall Unit 3 cooling tower, attendees came together to commemorate the efforts of the more than 5,000 workers currently onsite building two of the country’s first new nuclear units in three decades.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7398151-georgia-power-plant-vogtle-expansion-marks-year-of-progress/
